SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE

The following table summarizes the shares of common stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the three months ended March 31, 2023 and 2022 as such shares would have had an anti-dilutive effect:

	As of March 31,
	2023		2022
Stock options (a)		146,191		11,500
Warrants (b)		16,725		-
Unvested restricted stock		181,887		179,180

^(a) Includes 144,191 shares underlying stock options assumed pursuant to the merger agreement with Precision Healing, Inc. (“Precision Healing”) in April 2022. See Note 3 for more information regarding the Precision Healing merger.

^(b) Shares underlying warrants assumed pursuant to the merger agreement with Precision Healing in April 2022. See Note 3 for more information regarding the Precision Healing merger.

SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES

Revenue streams from product sales and royalties are summarized below for the three months ended March 31, 2023 and 2022.

	Three Months Ended
	March 31,
	2023		2022
Product sales revenue	$	15,471,667	$	7,760,973
Royalty revenue		50,250		50,250
Total Net Revenue	$	15,521,917	$	7,811,223

SCHEDULE OF PROPERTY AND EQUIPMENT

	Useful	March 31,			December 31,
	Life	2023			2022
Computers	3-5 years	$	187,173		$	172,154
Office equipment	3-7 years		97,097			87,225
Furniture and fixtures	5-10 years		260,578			258,414
Leasehold improvements	2-5 years		19,631			19,631
Internal use software	5 years		1,618,999			1,618,998
			2,183,478			2,156,422
Less accumulated depreciation			(847,661	)		(739,986	)
Property and equipment, net		$	1,335,817		$	1,416,436

SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION

Balance December 31, 2022	$	7,166,691
Additions		-
Changes in fair value of earnout liabilities		(452,687	)
Settlements		-
Balance March 31, 2023	$	6,714,004